Experts urge genetic testing for all ALS patients, regardless of family history
'Global best practice recommendations' target 4 genes tied to disease
Written by |
With new treatments targeting specific genetic causes of ALS, an international team of experts has recommended testing for everyone diagnosed. (Image from iStock)
- Genetic testing should be offered to all individuals worldwide who are diagnosed with ALS, a team of experts says.
- Along with genetic counseling, such testing should be provided regardless of a patient's family history or financial situation.
- At a minimum, testing should screen for four key genes so as to aid clinical decisions and potential risk assessment for family members, the guidelines say.
A global group of experts is recommending that all individuals worldwide who are diagnosed with amyotrophic lateral sclerosis (ALS) be offered genetic testing alongside appropriate counseling and support.
The team, convened by the International Alliance of ALS/MND Associations, issued “global best practice recommendations” for ALS in a newly published paper. Among them, the experts urged at least basic genetic testing for all ALS patients, regardless of family history or financial situation.
The recommendations actually note that more comprehensive genetic testing, such as sequencing a person’s whole genome, is the aspirational goal. However, because this may not be feasible in healthcare systems with limited resources, the group recommended that, at a minimum, testing should look for mutations in four genes associated with ALS: SOD1, C9orf72, FUS, and TARDBP.
The guidelines also emphasize that genetic testing should be offered even in countries where gene-targeted treatments aren’t available. Genetic information can help inform clinical decisions, determine eligibility for clinical trials, and provide important insights into the potential risk of ALS among biological relatives, the team noted.
The paper, “Global best practice recommendations for genetic counselling and testing in amyotrophic lateral sclerosis,” was published in the journal Brain. The Alliance noted that the guidance was “developed through a structured, iterative consensus process incorporating clinical expertise, lived experience perspectives, published evidence, and global representation,” with the recommendations approved during an “in-person consensus meeting.”
A progressive neurological disorder, ALS results in increasing muscle weakness and eventually paralysis. Although its causes are not fully understood, genetic mutations have been identified in at least 20% of people with ALS, including those without a known family history of the disease.
New treatments such as Qalsoy target genetic cause of ALS
Identifying these mutations is becoming increasingly important as researchers develop treatments targeting specific genetic causes of ALS. One example is Qalsody (tofersen), which aims to treat ALS caused by mutations in the SOD1 gene and is conditionally approved in the U.S. and the European Union.
Because gene mutations cause some cases of ALS, genetic testing may provide important insights into the disease for a given patient. However, access to genetic testing varies considerably worldwide. Existing recommendations have been developed in countries with greater resources, but imbalances in access to testing and treatment make them difficult to implement in other settings.
This has led to debate about whether, when, and how to offer genetic testing for ALS patients. To address such questions, the Alliance convened a global, multidisciplinary group of experts to create recommendations outlining both minimum and aspirational standards for genetic testing in ALS.
After meeting, the experts recommended that genetic testing be offered to everyone diagnosed with ALS — accompanied by counseling before and after testing to help patients make informed decisions and understand their results.
Per the team, testing should generally be integrated into the diagnostic process or offered as soon as possible after a diagnosis is confirmed. Also, access to testing should not depend on whether patients can afford it or whether gene-targeted treatments are available in their country.
Importantly, offering testing should not be confused with requiring patients to undergo it, the experts noted. The decision should remain voluntary, with patients receiving enough information to make an informed decision, they said.
“A foundation of these recommendations is that the offer of genetic testing, supported by informed and context-appropriate counselling, constitutes the ethical minimum for equitable care,” the researchers wrote. “This approach emphasizes patient autonomy, informed choice, and transparency, while recognizing that access to testing and therapies remains highly variable worldwide.”
Experts also recommend genetic counseling for all patients
The experts noted that, ideally, genetic testing should be comprehensive, providing as much information as possible about a person’s genetic makeup. But this isn’t always feasible, the team noted, so they urged that, at a minimum, patients should be tested for mutations in four genes that are relatively common causes of ALS.
“The distinction between minimum and aspirational standards allows immediate adoption of minimum best practices while providing a clear goal as resources, infrastructure, and workforce capacity evolve,” the scientists wrote.
The recommendations also note that ALS patients undergoing genetic testing should ideally have access to a trained genetic counselor — a specialist in interpreting genetic information. But when access is limited, other members of the care team should try to fill the gap. If one-on-one counseling isn’t an option, delivering counseling in group settings may make it more accessible, the experts noted.
“These recommendations acknowledge that while comprehensive counselling by a trained genetic counsellor remains aspirational, meaningful counselling can still be delivered by trained members of the multidisciplinary team when specialist resources are limited,” the researchers wrote.
The distinction between minimum and aspirational standards allows immediate adoption of minimum best practices while providing a clear goal as resources, infrastructure, and workforce capacity evolve.
The guidelines also address how genetic information should be handled. Protecting patients’ privacy is paramount, particularly given the potential for genetic discrimination involving employment, insurance, and other aspects of daily life, the team noted.
If genetic testing results become available only after a patient has died, however, sharing findings with close relatives may be ethically appropriate, especially when a clinically or therapeutically actionable mutation is identified, according to the team. Such information could help relatives make decisions about their health and family planning.
The scientists noted that these recommendations will need to be updated as research uncovers more about the genetic underpinnings of ALS. The team also noted a need for similar guidelines for how to offer testing to biological relatives of people who are known to carry ALS-causing mutations.
Leave a comment
Fill in the required fields to post. Your email address will not be published.